Enhancing sepsis biomarker development: key considerations from public and private perspectivesJean‐François Llitjos, Enitan D. Carrol, Marcin F. Osuchowski et al.|Critical Care|2024Cited by 81
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trialBruno François, Pierre‐François Laterre, Sébastien Gibot et al.|Intensive Care Medicine|2020Cited by 71
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trialBruno François, Pierre‐François Laterre, Simon Lambden et al.|BMJ Open|2021Cited by 20